Phase II Study of Low-dose Everolimus Plus Weekly Cisplatin and 24-hour Infusion of High-dose 5-fluorouracil and Leucovorin for First-line Treatment of Metastatic or Recurrent Gastric Cancers

被引：1
|
作者：
Yeh, K. [1 ]
Shen, Y. C. [1 ]
Li, C. P.
Yen, C. J. [3 ]
Lin, Y. L. [1 ]
Lin, Z. Z. [1 ]
Chen, L. T. [4 ]
Su, W. C. [3 ]
Chao, Y. [2 ]
Cheng, A. L. [1 ]
机构：
[1] Natl Taiwan Univ Hosp, Taipei, Taiwan
[2] Taipei Vet Gen Hosp, Ctr Canc, Taipei, Taiwan
[3] Natl Cheng Kung Univ Hosp, Tainan 70428, Taiwan
[4] Natl Hlth Res Inst, Tainan, Taiwan
来源：
EUROPEAN JOURNAL OF CANCER | 2011年 / 47卷
关键词：
D O I：
10.1016/S0959-8049(11)71896-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S467 / S467
页数：1
相关论文
共 50 条
  • [1] Phase II study of weekly low-dose everolimus plus weekly 24-hour infusions of cisplatin and high-dose 5-fluorouracil and leucovorin for first-line treatment in patients with advanced gastric cancers
    Yeh, K.
    Shen, Y.
    Li, C.
    Yen, C.
    Hsu, C.
    Lin, Z.
    Chen, L.
    Su, W.
    Chao, Y.
    Cheng, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [2] Phase II Multicentered Study of Low-Dose Everolimus plus Cisplatin and Weekly 24-Hour Infusion of High-Dose 5-Fluorouracil and Leucovorin as First-Line Treatment for Patients with Advanced Gastric Cancer
    Shen, Ying-Chun
    Li, Chung-Pin
    Yen, Chia-Jui
    Hsu, Chiun
    Lin, Yu-Lin
    Lin, Zhong-Zhe
    Chen, Li-Tzong
    Su, Wu-Chou
    Chao, Yee
    Yeh, Kun-Huei
    Cheng, Ann-Lii
    ONCOLOGY, 2014, 87 (02) : 104 - 113
  • [3] PHASE II STUDY OF CETUXIMAB PLUS WEEKLY CISPLATIN AND 24-HOUR INFUSION OF HIGH-DOSE 5-FLUOROURACIL AND LEUCOVORIN FOR THE FIRST-LINE TREATMENT OF ADVANCED GASTRIC CANCER
    Yeh, K. H.
    Hsu, C. H.
    Hsu, C.
    Huang, C. L.
    Lin, C. H.
    Shen, Y. C.
    Wu, S. L.
    Chiou, T. J.
    Chao, Y.
    Cheng, A. L.
    ANNALS OF ONCOLOGY, 2008, 19 : 174 - 174
  • [4] Phase II study of cetuximab plus weekly cisplatin and 24-hour infusion of high-dose 5-fluorouracil and leucovorin for the first-line treatment of advanced gastric cancer
    Yeh, K.
    Hsu, C.
    Hsu, C.
    Lin, C.
    Shen, Y.
    Wu, S.
    Chiou, T.
    Chao, Y.
    Cheng, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [5] A phase II study of weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin (HDFL) in the treatment of recurrent or metastatic colorectal cancers
    Yeh, KH
    Cheng, AL
    Lin, MT
    Hong, RL
    Hsu, CH
    Lin, JF
    Chang, KJ
    Lee, PH
    Chen, YC
    ANTICANCER RESEARCH, 1997, 17 (5B) : 3867 - 3871
  • [6] Phase II study of weekly paclitaxel and 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of recurrent or metastatic gastric cancer
    Yeh, KH
    Lu, YS
    Hsu, CH
    Lin, JF
    Hsu, C
    Kuo, SH
    Li, SJ
    Cheng, AL
    ONCOLOGY, 2005, 69 (01) : 88 - 95
  • [7] Weekly paclitaxel, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil plus leucovorin (weekly TP-HDFL) in patients with metastatic or recurrent esophageal cancer
    Huang, T.
    Tsai, Y.
    Lin, C.
    Cheng, A.
    Yeh, K.
    Hsu, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [8] A phase II study of weekly low-dose paclitaxel plus 24-hour infusion of cisplatin as first-line chemotherapy for metastatic breast cancer (MBC)
    Shen, Y.
    Hsu, C.
    Kuo, S.
    Lu, Y.
    Lin, C.
    Huang, C.
    Cheng, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [9] Phase II study with cisplatin and paclitaxel in combination with weekly high-dose 24 h infusional 5-fluorouracil/leucovorin for first-line treatment of metastatic breast cancer
    Klaassen, U
    Wilke, H
    Weyhofen, R
    Harstrick, A
    Eberhardt, W
    Muller, C
    Korn, M
    Hanske, M
    Diergarten, K
    Seeber, S
    ANTI-CANCER DRUGS, 1998, 9 (03) : 203 - 207
  • [10] Phase II study of weekly vinorelbine and 24-h infusion of high-dose 5-fluorouracil plus leucovorin as first-line treatment of advanced breast cancer
    Yeh, KH
    Lu, YS
    Hsu, CH
    Lin, JF
    Chao, HJ
    Huang, TC
    Chung, CY
    Chang, CS
    Yang, CH
    Cheng, AL
    BRITISH JOURNAL OF CANCER, 2005, 92 (06) : 1013 - 1018
12345